Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency

Journal of Immunology

Volumn 185, Issue 5, 2010, Pages 2721-2729

  Wingender, Gerhard ^a   Krebs, Philippe ^b   Beutler, Bruce ^b   Kronenberg, Mitchell ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; FAS ANTIGEN; GLYCOLIPID; GRANZYME; PERFORIN; ALPHA GALACTOSYLCERAMIDE; ALPHA-GALACTOSYLCERAMIDE; CD1D1 PROTEIN, MOUSE; EPITOPE; FAS LIGAND; GALACTOSYLCERAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THYMUS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOTOXICITY TEST; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METHODOLOGY; MOUSE MUTANT; NATURAL KILLER T CELL; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTIGENS, CD1D; ANTIGENS, CD95; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FAS LIGAND PROTEIN; GALACTOSYLCERAMIDES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NATURAL KILLER T-CELLS; UP-REGULATION;

EID: 78049384898     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001018     Document Type: Article

References (86)

1. Morita, M., K. Motoki, K. Akimoto, T. Natori, T. Sakai, E. Sawa, K. Yamaji, Y. Koezuka, E. Kobayashi, and H. Fukushima. 1995. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 38: 2176-2187.
2. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of va14 NKT cells by glycosylceramides. Science 278: 1626-1629.
3. Swann, J. B., J. M. Coquet, M. J. Smyth, and D. I. Godfrey. 2007. CD1-restricted T cells and tumor immunity. Curr. Top. Microbiol. Immunol. 314: 293-323.
4. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23: 877-900.
5. Terabe, M., and J. A. Berzofsky. 2007. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28: 491-496.
6. Tupin, E., Y. Kinjo, and M. Kronenberg. 2007. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5: 405-417.
7. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J. Immunol. 154: 4333-4340.
8. + αβ T cells in the lungs of euthymic and athymic mice. Immunology 88: 82-89.
9. + αβ T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J. Immunol. 156: 2436-2442.
10. Takeda, K., Y. Hayakawa, M. Atsuta, S. Hong, L. Van Kaer, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura. 2000. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int. Immunol. 12: 909-914.
11. + αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J. Immunol. 156: 3366-3373.
12. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623-1626.
13. + T cells in IL-12-induced immune responses in vivo. J. Immunol. 160: 16-19.
14. Smyth, M. J., M. Taniguchi, and S. E. Street. 2000. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J. Immunol. 165: 2665-2670.
15. Nakagawa, R., K. Motoki, H. Nakamura, H. Ueno, R. Iijima, A. Yamauchi, S. Tsuyuki, T. Inamoto, and Y. Koezuka. 1998. Antitumor activity of α-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol. Res. 10: 561-568.
16. Nakagawa, R., K. Motoki, H. Ueno, R. Iijima, H. Nakamura, E. Kobayashi, A. Shimosaka, and Y. Koezuka. 1998. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide, KRN7000. Cancer Res. 58: 1202-1207.
17. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α- galactosylceramide in mice. J. Immunol. 166: 6578-6584.
18. Nakagawa, R., I. Serizawa, K. Motoki, M. Sato, H. Ueno, R. Iijima, H. Nakamura, A. Shimosaka, and Y. Koezuka. 2000. Antitumor activity of α-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol. Res. 12: 51-58.
19. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, H. Sato, E. Kondo, M. Harada, H. Koseki, T. Nakayama, et al. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. USA 95: 5690-5693.
20. Kawano, T.,T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. 1999. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res. 59: 5102-5105.
21. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189: 1121-1128.
22. Toura, I., T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai, and M. Taniguchi. 1999. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J. Immunol. 163: 2387-2391.
23. +NKcells in vitro. J. Immunol. 165: 1659-1664.
24. Metelitsa, L. S., O. V. Naidenko, A. Kant, H. W. Wu, M. J. Loza, B. Perussia, M. Kronenberg, and R. C. Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167: 3114-3122.
25. Smyth, M. J., N. Y. Crowe, and D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13: 459-463.
26. Hayakawa, Y., K. Takeda, H. Yagita, M. J. Smyth, L. Van Kaer, K. Okumura, and I. Saiki. 2002. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 100: 1728-1733.
27. Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, L. Van Kaer, I. Saiki, and K. Okumura. 2001. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. 31: 1720-1727.
28. + NKT cells. Eur. J. Immunol. 36: 570-582.
29. Hermans, I. F., J. D. Silk, J. Yang, M. J. Palmowski, U. Gileadi, C. McCarthy, M. Salio, F. Ronchese, and V. Cerundolo. 2004. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 285: 25-40.
30. Gansuvd, B., M. Hagihara, Y. Yu, H. Inoue, Y. Ueda, T. Tsuchiya, A. Masui, K. Ando, Y. Nakamura, N. Munkhtuvshin, et al. 2002. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum. Immunol. 63: 164-175.
31. Coles, R. M., S. N. Mueller, W. R. Heath, F. R. Carbone, and A. G. Brooks. 2002. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol. 168: 834-838.
32. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, and M. Kronenberg. 1998. CD1d-mediated recognition of an α- galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188: 1521-1528.
33. Sidobre, S., and M. Kronenberg. 2002. CD1 tetramers: a powerful tool for the analysis of glycolipid-reactive T cells. J. Immunol. Methods 268: 107-121.
34. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C. R. Wang, Y. Koezuka, and M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192: 741-754.
35. Roederer, M., Z. Darzynkiewicz, and D. R. Parks. 2004. Guidelines for the presentation of flow cytometric data. Methods Cell Biol. 75: 241-256.
36. 2-microglobulin- dependent and independent forms. J. Immunol. 161: 1710-1717.
37. Roark, J. H., S. H. Park, J. Jayawardena, U. Kavita, M. Shannon, and A. Bendelac. 1998. CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J. Immunol. 160: 3121-3127.
38. Bendelac, A., M. N. Rivera, S. H. Park, and J. H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15: 535-562.
39. Kronenberg, M., and L. Gapin. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2: 557-568.
40. Crowe, N. Y., J. M. Coquet, S. P. Berzins, K. Kyparissoudis, R. Keating, D. G. Pellicci, Y. Hayakawa, D. I. Godfrey, and M. J. Smyth. 2005. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202: 1279-1288.
41. Knolle, P. A., and A. Limmer. 2001. Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol. 22: 432-437.
42. Crispe, I. N. 2003. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3: 51-62.
43. Sullivan, B. A., N. A. Nagarajan, G. Wingender, J. Wang, I. Scott, M. Tsuji, R. W. Franck, S. A. Porcelli, D. M. Zajonc, and M. Kronenberg. 2010. Mechanisms for glycolipid antigen-driven cytokine polarization by Vα14i NKT cells. J. Immunol. 184: 141-153.
44. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
45. Oki, S., A. Chiba, T. Yamamura, and S. Miyake. 2004. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113: 1631-1640.
46. Stanic, A. K., R. Shashidharamurthy, J. S. Bezbradica, N. Matsuki, Y. Yoshimura, S. Miyake, E. Y. Choi, T. D. Schell, L. Van Kaer, S. S. Tevethia, et al. 2003. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor. [corrected] J. Immunol. 171: 4539-4551.
47. Wu, D., D. M. Zajonc, M. Fujio, B. A. Sullivan, Y. Kinjo, M. Kronenberg, I. A. Wilson, and C. H. Wong. 2006. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc. Natl. Acad. Sci. USA 103: 3972-3977.
48. Kinjo, Y., D. Wu, G. Kim, G. W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C. H. Wong, and M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520-525.
49. Smyth, M. J., N. Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D. I. Godfrey. 2002. NKT cells: conductors of tumor immunity? Curr. Opin. Immunol. 14: 165-171.
50. Fiedler, T., W. Walter, T. E. Reichert, and M. J. Maeurer. 2002. Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules? Int. J. Cancer 98: 389-397.
51. Shimizu, K., A. Goto, M. Fukui, M. Taniguchi, and S. Fujii. 2007. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J. Immunol. 178: 2853-2861.
52. Shimizu, K., Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S. Fujii. 2007. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med. 204: 2641-2653.
53. Yang, G., J. Schmieg, M. Tsuji, and R. W. Franck. 2004. The C-glycoside analogue of the immunostimulant α-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew. Chem. Int. Ed. Engl. 43: 3818-3822.
54. Schmieg, J., G. Yang, R. W. Franck, and M. Tsuji. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198: 1631-1641.
55. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu, III, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529.
56. Balaji, K. N., N. Schaschke, W. Machleidt, M. Catalfamo, and P. A. Henkart. 2002. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196: 493-503.
57. Sun, J., C. H. Bird, V. Sutton, L. McDonald, P. B. Coughlin, T. A. De Jong, J. A. Trapani, and P. I. Bird. 1996. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 271: 27802-27809.
58. Cunningham, T. D., X. Jiang, and D. J. Shapiro. 2007. Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell. Immunol. 245: 32-41.
59. Barry, M., and R. C. Bleackley. 2002. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2: 401-409.
60. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20: 323-370.
61. Kaneko, Y., M. Harada, T. Kawano, M. Yamashita, Y. Shibata, F. Gejyo, T. Nakayama, and M. Taniguchi. 2000. Augmentation of Va14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191: 105-114.
62. Mattarollo, S. R., T. Kenna, M. Nieda, and A. J. Nicol. 2006. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Va24+ NKT cell-mediated cytotoxicity. Int. J. Cancer 119: 1630-1637.
63. + Vα24 NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97: 2067-2074.
64. + natural killer T cells activated by α-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 99: 229-234.
65. Metelitsa, L. S., K. I. Weinberg, P. D. Emanuel, and R. C. Seeger. 2003. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17: 1068-1077.
66. + NKT cells activated by α-glycosylceramide- pulsed monocyte-derived dendritic cells. J. Immunol. 164: 4458-4464.
67. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99: 1259-1266.
68. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127.
69. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
70. Eberl, G., and H. R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30: 985-992.
71. Kakimi, K., L. G. Guidotti, Y. Koezuka, and F. V. Chisari. 2000. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192: 921-930.
72. Kinjo, Y., and M. Kronenberg. 2005. Vα14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J. Clin. Immunol. 25: 522-533.
73. Nishimura, T., H. Kitamura, K. Iwakabe, T. Yahata, A. Ohta, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, T. Kawano, et al. 2000. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 12: 987-994.
74. Brutkiewicz, R. R., and V. Sriram. 2002. Natural killer T (NKT) cells and their role in antitumor immunity. Crit. Rev. Oncol. Hematol. 41: 287-298.
75. Haraguchi, K., T. Takahashi, F. Nakahara, A. Matsumoto, M. Kurokawa, S. Ogawa, H. Oda, H. Hirai, and S. Chiba. 2006. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk. Lymphoma 47: 2218-2223.
76. Fais, F., F. Morabito, C. Stelitano, V. Callea, S. Zanardi, M. Scudeletti, P. Varese, E. Ciccone, and C. E. Grossi. 2004. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates α-galactosylceramide presentation to natural killer T lymphocytes. Int. J. Cancer 109: 402-411.
77. Fais, F., C. Tenca, G. Cimino, V. Coletti, S. Zanardi, D. Bagnara, D. Saverino, D. Zarcone, G. De Rossi, E. Ciccone, and C. E. Grossi. 2005. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 19: 551-556.
78. Nowak, M., F. Kopp, K. Roelofs-Haarhuis, X. Wu, and E. Gleichmann. 2006. Oral nickel tolerance: Fas ligand-expressing invariant NK T cells promote tolerance induction by eliciting apoptotic death of antigen-carrying, effete B cells. J. Immunol. 176: 4581-4589.
79. - αβ T cells and endogenous IL-4 in non-MHC-restricted rejection of embryonal carcinoma in genetically resistant mice. J. Immunol. 158: 5338-5348.
80. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA 100: 10902-10906.
81. Smyth, M. J., M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201: 1973-1985.
82. Böhm, W., S. Thoma, F. Leithäuser, P. Möller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161: 897-908.
83. Peter, I., A. Mezzacasa, P. LeDonne, R. Dummer, and S. Hemmi. 2001. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res. 11: 21-30.
84. Fujii, S., K. Shimizu, M. Kronenberg, and R. M. Steinman. 2002. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3: 867-874.
85. Fujii, S., K. Shimizu, H. Hemmi, M. Fukui, A. J. Bonito, G. Chen, R. W. Franck, M. Tsuji, and R. M. Steinman. 2006. Glycolipid α-C- galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl. Acad. Sci. USA 103: 11252-11257.
86. Motohashi, S., and T. Nakayama. 2008. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 99: 638-645.